tbuckley/cabot-search huggingface dataset:
Laboratory Data
Authors: William G. Bernhard
Journal: JAMA (1968)

<h3>To the Editor:—</h3> During 1967 information with respect to medical laboratories was repeatedly presented to Congress by the Department of Health, Education, and Welfare which was a confused and sometimes inappropriate application of data from very limited surveys, mostly from Public Health Laboratories, including Indian Bureau and Federal Prison hospitals. The results of such surveys were assumed to apply to all hospitals in the United States. The conclusions drawn for the congressmen and senators were that 20 million tests per year are erroneous and that $470 million is being wasted yearly. These conclusions and the data (or lack of it) upon which they were based have been carefully reviewed and a detailed report has been published in the Congressional Record for Dec 14, 1967, (H.16075-78). Included in this report are facts which show, for example, that clinical chemistry tests are being judged by surveys conducted in the United States 15
Objectionable Photographs.
Authors: N.S. Davis
Journal: JAMA (1894)

Chicago, Ill., Dec. 29, 1893. <h3>To the Editor:</h3> —I have this day received a copy of a calendar for 1894, in six sheets hitched together by a string, purporting to have been issued by or in commendation of<i>Maltine and its combinations</i>. On each sheet is the picture of some well-known physician, underneath it a paragraph highly commendatory of the Maltine, and below that the calendar of two months of the year 1894. On one page is what purports to be a copy of some photograph of myself. As I have never prescribed an ounce of Maltine, nor written a line concerning it in my life, I presume the manufacturers have taken this method to inflict punishment. And certainly they could not have devised a more contemptible or meaner method if they had searched the records of meanness for half a century. If you will give this a place in
Levodopa and melanoma
Authors: J. Fermaglich
Journal: JAMA (1979)

<h3>To the Editor.—</h3> Based on personal experience with a single case of Parkinson's disease and malignant melanoma and an incomplete review of the literature, Sober and Wick (240:554, 1978) conclude that levodopa should be administered to patients with Parkinson's disease who have a history of melanoma. This recommendation is particularly sobering in view of their own studies.<sup>1</sup> Three additional cases of the combination of malignant melanoma and Parkinson's disease have been reported.<sup>2,3</sup>In two, surgical excision of the melanomas was accomplished before the onset of Parkinson's disease, and neither patient was treated with levodopa. The third patient's condition was diagnosed as malignant melanoma eight years after treatment with levodopa and four years after treatment with levodopa and methyldopa. All three have now been treated for periods in excess of six months with bromocriptine, and although therapy had to be terminated in one patient because of centrally mediated complications of
Measurement Variability Associated with KXRF Bone Lead Measurement in Young Adults
Authors: Jane A. Hoppin, Antonio Aro, Howard Hu, P. Barry Ryan
Journal: Environmental Health Perspectives (2000)

In vivo bone lead measurement using K X-ray fluorescence (KXRF) has been used to estimate long-term lead exposure, especially in adults. Relatively few studies have been conducted on young subjects with this technique. To explore the measurement variability of KXRF bone lead measurements in young subjects, the tibiae of two male cadavers from Boston, Massachusetts, 17 and 20 years of age, were obtained for repeated bone lead measurements. Bone lead concentrations were measured using a grid of nine locations, 1 cm apart, centered at the midpoint of the tibia. Each location was sampled using five 60-min measurements. Measured concentrations ranged from < 0 to 11.8 microg Pb/g bone mineral across a tibia with mean concentrations for the midpoint locations of 0.8 microg Pb/g bone mineral SD = 2.5 and 2.0 microg Pb/g bone mineral (SD = 1.9) for the left and right legs of the younger subject and 3.6 microg Pb/g bone mineral (SD = 2.6) and 6.0 microg Pb/g bone mineral (SD = 3.3) for the left and right legs of the older subject. Although bone lead concentrations did not vary significantly by measurement location in an individual leg, reported measurement uncertainty increased significantly at locations that were 1 cm from the center of the tibia horizontally (p < 0.0001). Symmetry in bone lead concentration between legs was observed for the 17-year-old subject. Potential asymmetry between the left and right legs was suggested for the 20-year-old subject (p = 0.06). These data describe the degree of variability that may be associated with bone lead measurements of young subjects with low bone lead concentrations using a standard spot-source KXRF instrument. Because of the importance of conducting additional research on adolescent lead toxicity, further improvements to the precision of KXRF measurement are needed.
Predictive value of single nucleotide polymorphisms (SNPs) in DNA repair genes in non-selected advanced colorectal cancer (CRC) patients (p) treated with oxaliplatin (OXA) plus 5-Fluorouracil (5-FU) first-line chemotherapy (CT)
Authors: E. Martinez-Balibrea, J. L. Manzano, S. Catot, A. Martinez-Cardus, L. Nuñez, M. Taron, A. Abad
Journal: Journal of Clinical Oncology (2004)

3680 Background: OXA cause DNA cross-linking and oxidative damage. SNPs in DNA repair genes are associated with inter-individual differences in DNA repair capacity and can explain the heterogeneity in OXA response. We assessed SNPs in four DNA repair genes belonging to three of the major DNA repair pathways: nucleotide excision repair (XPD Lys751Gln; ERCC1 C118T); base excision repair (XRCC1Arg399Gln) and homologous recombination repair (XRCC3Thr241Met) and correlated the results with outcome in OXA/5FU-treated advanced CRC p. Methods: 39 consecutive advanced CRC p were included. TaqMan 5' nuclease assay was used to examine SNPs from DNA isolated from peripheral blood lymphocytes. Results: p characteristics: median age: 59 years (33–72); 59% male. Overall outcome: median time to progression (TTP): 7 months (m); overall response rate (OR): 46%. Homozygosity for wild type alleles (Lys, C, Arg and Thr, respectively) was considered a favorable genotype for OXA response. OR according to genotype (favorable/unfavorable): XPD23 47.8/43.8%; ERCC1 33,3/47,2%; XRCC1 47.4/45% and XRCC3 44.4/38.1% (P=ns). No differences in TTP according to single genotype were observed. In contrast, when we analyzed the impact of allele combination, p carrying 4 or more unfavorable alleles (47% p) had a shorter TTP than those carrying less than 4 (53% p) (4.5m vs 7.5m; P=0.07). Conclusions: The impact of allele combination in DNA repair genes may be a key predictive marker of chemosensitivity. The prospective inclusion and genotyping of advanced CRC p is needed to clarify the role of these SNPs in predicting response to OXA/5FU. No significant financial relationships to disclose.
“Aspirin”—A Common Name
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CONSTIPATION
Authors: A. J. BEAMS
Journal: JAMA (1930)

We recognize that there is much lack of agreement on a definite line of demarcation between atonic constipation and spastic constipation. But since each diet is adapted to the individual needs and is advised only on the physician's specific recommendation for a certain diet, we feel that a basic outline is necessary for each condition. <h3>SUGGESTIONS FOR A "ROUGH" DIET FOR CONSTIPATION</h3><h3>FOODS ALLOWED</h3><h3>Beverages:</h3> Buttermilk, weak coffee, fruit juices, Kaffee Hag, milk, postum, weak tea. <h3>Soups:</h3> Beef broth, chicken broth, mutton broth, tomato soup, veal broth, vegetable soup (cream soups made with cream and puréed vegetables). <h3>Breads:</h3> Bran bread, bran muffins, entire wheat bread. Eggs: Coddled, hard cooked, poached, scrambled over water and soft cooked. <h3>Fats:</h3> Butter, cream, oil, oleomargarine. <h3>Cereals:</h3> Bran, malt breakfast food, oatmeal, pettijohns, cracked wheat. <h3>Desserts:</h3> Apple snow, custard, gelatins, ice cream, prune whip, tapioca pudding. <h3>Fruits:</h3> Cooked—apples, apricots, cherries, cranberries, currants, figs, peaches, pears,
Toko-Ginecologia Practica, Madrid
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genomic Landscape of Young ATLL Patients Identifies Frequent Targetable CD28 Fusions
Authors: Noriaki Yoshida, Kay Shigemori, Samuel Y. Ng, Ajit Nirmal, Nicolas Donaldson, Nicolas Cordero, Kristen E. Stevenson, Xia Bu, Mai Takeuchi, Koichi Ohshima, Akinori Yoda, David M Weinstock
Journal: Blood (2019)
ECONOMIC TRENDS AND THE WEIGHT OF CHILDREN
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Front Cover Image, Volume 41, Issue 4
Authors: Muya Xiong, Haixia Su, Wenfeng Zhao, Hang Xie, Qiang Shao, Yechun Xu
Journal: Medicinal Research Reviews (2021)

The cover image is based on the Review Article What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design by Muya Xiong et al., https://doi.org/10.1002/med.21783.
CLINICAL MEMORANDA
Journal: BMJ (1940)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following CLINICAL MEMORANDA Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
INFLUENCE OF ANESTHESIA ON EXPERIMENTAL NEUROTROPIC VIRUS INFECTIONS
Authors: S. Edward Sulkin, Christine Zarafonetis
Journal: The Journal of Experimental Medicine (1947)

1. Experimental neurotropic virus infections previously shown to be altered by ether anesthesia are caused by viruses destroyed in vitro by anesthetic ether; this group includes the viruses of Eastern equine encephalomyelitis, Western equine encephalomyelitis, and St. Louis encephalitis. 2. Experimental neurotropic virus infections which were not altered by ether anesthesia are caused by viruses which are refractory to the in vitro virucidal activity of even large amounts of anesthetic ether; this group includes the viruses of poliomyelitis (Lansing) and rabies. 3. Quantitative studies of the in vitro virucidal activity of ether indicate that concentrations of this anesthetic within the range found in central nervous system tissues of anesthetized animals possess no virucidal activity. 4. The lowest concentration of ether possessing significant virucidal capacity is more than fifteen times the maximum concentration of the anesthetic tolerated by the experimental animal. 5. Concentrations of ether 50 to 100 times the maximum amount tolerated by the anesthetized animal are capable of destroying large amounts of susceptible viruses, the average lethal dose (LD50) being reduced more than 5 log units. 6. On the basis of the studies presented in this report, it cannot be concluded that direct virucidal activity of ether is not the underlying mechanism of the inhibition by anesthesia of certain experimental neurotropic virus infections. Indirect inhibition of the virus by the anesthetic through an alteration in the metabolism of either the host cell or the host animal as a whole appears at this point to be a more likely possibility.
Intracranial hemorrhage: cerebral amyloid angiopathy or nasal decongestants?
Authors: M. I. Weintraub
Journal: JAMA (1990)

<h3>In Reply.—</h3> I am grateful to Dr Weintraub for addressing the relationship of nasal decongestants, chiefly phenylpropanolamine, to stroke and intracranial hemorrhage. The association between nasal decongestants and cerebral hemorrhage in the patient under consideration indeed implies a causal connection. Such a link is firmest when there exists definite evidence of vasculitis, or when the subject is a young person free of recognized risk factors for cerebrovascular disease. In this instance, however, the patient was old enough at presentation to harbor cerebral amyloid angiopathy (CAA). Although CAA is relatively uncommon in persons between 60 and 70 years old,<sup>1</sup>one of the 11 examples of cerebral hemorrhage due to CAA described by Gilbert and Vinters<sup>2</sup>closely resembles the case under discussion. This was a 61-year-old woman free of dementia with a large occipital hemorrage leading to death, who on pathological analysis proved to have CAA. The subsequent clinical course
The DDT muddlement
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage
Authors: Yusuke Kageyama, Zhongyan Zhang, Ricardo Roda, Masahiro Fukaya, Junko Wakabayashi, Nobunao Wakabayashi, Thomas W. Kensler, P. Hemachandra Reddy, Miho Iijima, Hiromi Sesaki
Journal: The Journal of Experimental Medicine (2012)
In the Beginning
Authors: Jerome O. Cantor
Journal: Annals of Internal Medicine (2017)

Ad Libitum7 March 2017In the BeginningJerome O. Cantor, BA, MDJerome O. Cantor, BA, MDFrom St. John's University, Queens, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M16-2908 Audio Reading - “In the Beginning” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "In the Beginning," by J.O. Cantor. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail We looked upon the wayward shellsThat washed against the shoreWhat message could we hope to findWithin their secret coreThe flawless turns of furrowed urnsAsserted symmetryWhile endless swarms of minute formsProfessed simplicityBut something more was hidden thereBeyond our intuitionThe unseen waves of ceaseless timeThat nurtured repetitionThey churned the interlocking wheelsThat brokered new connectionsBetween the streams of energyAbsolved of imperfectionsThen strands of random residuesThat slowly came togetherWere thrust about with rhythmic turnsIn sympathetic measureAnd when these nodes had coalescedInto primeval songThey filled the ancient void with tunesThat carried life along Author, Article, and Disclosure InformationAffiliations: From St. John's University, Queens, New York.Current Author Address: Jerome Cantor, MD, Department of Pharmaceutical Sciences, St. John's University College of Pharmacy and Health Sciences, 8000 Utopia Parkway, Queens, NY 11439; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “In the Beginning” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "In the Beginning," by J.O. Cantor. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 7 March 2017Volume 166, Issue 5Page: 372KeywordsRivers ePublished: 7 March 2017 Issue Published: 7 March 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
On-treatment progression-free survival analysis of aflibercept-FOLFIRI treatment within 28 days of progression in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.
Authors: David Raymond Ferry, Tae Won Kim, Tormod Kyrre Guren, Jayesh Desai, Luis Marcelo Villanueva, Michael L. Andria, Eric Van Cutsem, Josep Tabernero
Journal: Journal of Clinical Oncology (2013)

469 Background: The phase III VELOUR study demonstrated that adding the novel antiangiogenic agent aflibercept (known as ziv-aflibercept in the United States) to FOLFIRI in patients with metastatic colorectal cancer previously treated with oxaliplatin significantly improved overall survival, progression-free survival (PFS), and overall response rate versus placebo-FOLFIRI. We performed an additional analysis of PFS “on-treatment,” censoring events that occurred more than 28 days after last treatment dose. Methods: Patients were randomized to receive aflibercept 4 mg/kg or placebo every 2 weeks in combination with FOLFIRI. An independent review committee determined progression based on radiologic review. PFS was estimated using Kaplan-Meier analysis, with censoring of events after the last dose plus 28 days. Treatment groups were compared using a log-rank test stratified by ECOG performance status and prior bevacizumab therapy. Hazard ratio (HR) and confidence interval (CI) were estimated using a Cox proportional hazard model. Results: On-treatment PFS results are shown in the Table. Patients on aflibercept-FOLFIRI showed significantly increased on-treatment PFS compared with patients on placebo-FOLFIRI. More patients were censored in the aflibercept arm due to adverse events, thus decreasing the number of events. Conclusions: On-treatment PFS with aflibercept-FOLFIRI was significantly increased compared with placebo-FOLFIRI, which is consistent with the PFS benefit observed in the primary analysis. Clinical trial information: NCT00561470. [Table: see text]
Negro enrollment in medical schools
Authors: A. E. Crowley
Journal: JAMA (1969)

For the past decade more and more attention has been directed to disadvantaged groups in the American population. Many educational institutions are showing an increasing awareness of the need to give special consideration to persons from impoverished backgrounds, specifically the American Negroes. Because Negroes are underrepresented in the medical profession, educators in that field are also becoming interested in this problem. Even though more than 11% of the nation's population is Negro, less than 2% of American physicians are black. Or to put it another way, among white citizens, one American in 560 becomes a doctor; among Negroes, it is one in 3,800 (<i>Statistical Abstracts of the United States, 1968</i>, Bureau of Census, p 23).